Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

NASDAQ:CARA opened at $4.90 on Monday. Cara Therapeutics has a 52-week low of $2.71 and a 52-week high of $10.44. The company has a market cap of $22.41 million, a P/E ratio of -0.23 and a beta of 0.41. The stock’s 50-day simple moving average is $5.05 and its 200 day simple moving average is $4.37.

Institutional Investors Weigh In On Cara Therapeutics

Large investors have recently made changes to their positions in the stock. FMR LLC raised its position in Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 32,789 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Cara Therapeutics during the 3rd quarter worth about $29,000. Shay Capital LLC bought a new stake in shares of Cara Therapeutics in the 4th quarter valued at about $524,000. Rockefeller Capital Management L.P. acquired a new stake in Cara Therapeutics in the 4th quarter valued at about $953,000. Finally, Curi RMB Capital LLC bought a new position in Cara Therapeutics during the fourth quarter worth about $277,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.